Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Poornima Sood

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 21, 2016
Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomesDaniel Zimpfer, Ivan Netuka, Jan D Schmitto, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 10, 2010
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysisAshok Seth, Patrick W Serruys, Alexandra Lansky, et al.
European Journal of Heart Failure|July 28, 2018
Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark StudyJan D Schmitto, Yuriy Pya, Daniel Zimpfer, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trialsDean J Kereiakes, Krishnankutty Sudhir, James B Hermiller, et al.
The American Journal of Cardiology|April 3, 2012
Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three yearsAlexandra J Lansky, Somjot S Brar, Manejeh Yaqub, et al.
The American Journal of Cardiology|August 10, 2010
Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysisHiromasa Otake, Junya Ako, Masao Yamasaki, et al.
The American Journal of Cardiology|April 16, 2018
Efficacy and Safety of the HeartMate Percutaneous Heart Pump During High-Risk Percutaneous Coronary Intervention (from the SHIELD I Trial)Dariusz Dudek, Adrian Ebner, Robert Sobczyński, et al.
European Journal of Heart Failure|June 18, 2021
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trialMandeep R Mehra, Daniel L Crandall, Finn Gustafsson, et al.
The American Journal of Cardiology|January 25, 2011
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial)Vivian G Ng, Alexandra J Lansky, James B Hermiller, et al.
Journal of the American College of Cardiology|April 26, 2011
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trialGregg W Stone, Ali Rizvi, Krishnankutty Sudhir, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 21, 2016
Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomesDaniel Zimpfer, Ivan Netuka, Jan D Schmitto, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 10, 2010
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysisAshok Seth, Patrick W Serruys, Alexandra Lansky, et al.
European Journal of Heart Failure|July 28, 2018
Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark StudyJan D Schmitto, Yuriy Pya, Daniel Zimpfer, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trialsDean J Kereiakes, Krishnankutty Sudhir, James B Hermiller, et al.
The American Journal of Cardiology|April 3, 2012
Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three yearsAlexandra J Lansky, Somjot S Brar, Manejeh Yaqub, et al.
The American Journal of Cardiology|August 10, 2010
Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysisHiromasa Otake, Junya Ako, Masao Yamasaki, et al.
The American Journal of Cardiology|April 16, 2018
Efficacy and Safety of the HeartMate Percutaneous Heart Pump During High-Risk Percutaneous Coronary Intervention (from the SHIELD I Trial)Dariusz Dudek, Adrian Ebner, Robert Sobczyński, et al.
European Journal of Heart Failure|June 18, 2021
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trialMandeep R Mehra, Daniel L Crandall, Finn Gustafsson, et al.
The American Journal of Cardiology|January 25, 2011
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial)Vivian G Ng, Alexandra J Lansky, James B Hermiller, et al.
Journal of the American College of Cardiology|April 26, 2011
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trialGregg W Stone, Ali Rizvi, Krishnankutty Sudhir, et al.
Pageof 5